Platform / Therapeutics
Radiation that reaches CNS tumors.
Inside the central nervous system (CNS), the blood-brain barrier holds most treatments back, and healthy brain and spinal tissue tolerate limited radiation. Cerenome’s therapeutics platform is designed to deliver radiation directly to tumors, sparing healthy tissue.
Why It Matters
Why the brain and spine change the math.
Outside the CNS, oncology has more room to work with: systemic drugs can circulate freely, surgeons can take a wider margin, radiation fields can be more generous. None of that holds inside the skull or spinal canal.
The blood-brain barrier that protects the central nervous system also limits how much treatment reaches a tumor. Healthy brain and spinal cord tissue tolerate only so much radiation. And cancer moving through the cerebrospinal fluid is diffuse by nature, with no single target to aim at.
1. Aman R, Desbassarie F, Lubis AR, Ardiansyah IR. Prognostic factors and survival of recurrent glioblastoma: a systematic review. Folia Med (Plovdiv). 2025;67(3). doi:10.3897/folmed.67.e142227
More than 90% of glioblastomas recur, typically within 6 to 9 months of first treatment.1
Why this approach matters.
Hear from Cerenome’s President & CEO on how REYOBIQ™ is integral to the platform, and why targeted radiotherapy matters for these cancers.
Every dose teaches the system.
Within Cerenome’s CNS oncology platform, every dose administered is also a measurement: how the tumor responded, at what dose, over what timeline. That response feeds the platform’s data layer, helping inform how the next case is read and treated. In leptomeningeal metastases, detection and treatment happen in the same place: CNSide® measures tumor cells in the cerebrospinal fluid, and REYOBIQ™ is delivered into it, so response can be tracked directly.
Advancing through the clinic.
REYOBIQ™ is investigational and moving through clinical development. Here is where the program stands today.
On the record.
The program’s early findings are already in the peer-reviewed literature and in front of the clinical community.
Phase 1 REYOBIQ™ results in recurrent glioblastoma were published in Nature Communications (Brenner et al, March 2025).
ReSPECT-LM data in leptomeningeal metastases have been presented at the SNO Annual Conference (November 2026).
Backed to move forward.
Regulators and non-dilutive funders have supported REYOBIQ™’s path through development.
U.S. FDA has granted REYOBIQ™ five regulatory designations: Orphan Drug Designation for glioblastoma; Orphan Drug Designation for leptomeningeal metastases in breast cancer and lung cancer patients; and Fast Track Designation for leptomeningeal metastases and recurrent glioblastoma.
Three active ReSPECT™ trials, backed by non-dilutive funding from the National Cancer Institute, CPRIT, and the U.S. Department of Defense.
REYOBIQ™ is an investigational therapy. It has not been approved by the FDA, and its safety and effectiveness have not been established.

“This [trial] has changed my life because I’m here. I’m still here.”
Marlyn C.
ReSPECT-LM Clinical Trial Participant
Actor portrayal
REYOBIQ™ up close.
REYOBIQ™ is the investigational radiotherapeutic that powers Cerenome’s therapeutics capability. For full clinical, regulatory, and trial detail, visit the dedicated product page.